March 12-13, 2018

Hilton San Francisco Airport Bayfront | San Francisco, CA

Cannabis Partnerships Congress

Advancing Cannabinoid Science by Driving Effective Research and Overcoming Hurdles in Therapeutic Production and Regulatory Approval

Featured Speakers

CHAIRS

Bruce Bloom, *CEO*
CURES WITHIN REACH

Dean Petkanas,
Chief Medical Officer, **KANNALIFE SCIENCES**

Jeremy Unruh,
General Counsel,
PHARMACANN LLC

Thoma Kikis,
Chief Marketing Officer,
KANNALIFE SCIENCES

Veronica Arroyave,
Sr Director, Global Health Programs,
PARTNERSHIP FOR QUALITY MEDICAL DONATIONS

Lezli Engelking,
President and Founder,
FOCUS

Elias Jackson, Ph.D.,
CEO,
VYRIPHARM

Kimberly Lincoln,
Manufacturing Scientist,
ROCHE

Brian Fisher,
VP of Operations and Corporate Partnerships,
THE STURGE-WEBER FOUNDATION

Jeffrey Chen,
Director,
UCLA CANNABIS RESEARCH INITIATIVE

Featured Topics

Governmental and Regulatory

- Regulatory hurdles and anticipated changes
- Patient needs in medicinal cannabis
- Exploring the collaborative environment in associations or unions
- Establishing and adopting industry quality standards

Patient Advocacy

- Driving the research through patient-led requests (PTSD, stroke, neuroprotection)
- Understanding patient needs in cannabidiol neuroprotection and recovery

Academic/Research

- Lab-based case for healthcare driven cannabis efficacy
- Science and economics in quality control phylos science
- Understanding the role of cannabis in a cross-section of pathologies
- Cannabis quality controls for consistent and effective ingredients

Medical

- Medical relevance and proven areas of efficacy
- Navigating barriers to effective research
- Cannabis efficacy in Immune Therapy

Analytical

- Quality Control to decrease time to compound approval
- Cannabis testing for regulatory/compliance standardization

Dear Colleague,

The Cannabis Partnership Congress brings together all of the key stakeholders in a collaborative environment to face the scientific, medicinal, and governmental challenges of cannabis-based product development. Despite recent changes in state policy and the increasing rate of cannabis use and its implications for health, the federal government has yet to legalize cannabis. When facing the continued restrictions on research into the health benefits of cannabis, what strategies must pharma companies follow to bring these therapeutics to market?

Clinical research with cannabis needs special approval from FDA, while obtaining the plants themselves involves a separate time-consuming process through NIDA. The Cannabis Partnership Congress helps you navigate all of these regulatory and development challenges.

Join us this March in San Francisco and learn how to:

- Face the regulatory restrictions on cannabis R&D
- Develop industrial standards for cannabis
- Ensure compliance in cannabis marketing
- Weave cannabis into your rare disease pipeline
- Analyze the future of cannabis lab research

....and much more! We look forward to seeing you there!

WHO SHOULD ATTEND

This conference is designed for representatives from pharmaceutical, medical device, and biotechnology companies with responsibilities in the following areas:

- Cannabis
- Cannabinoid Science
- Strategic Partnerships
- Program and Pharmaceutical Portfolio Development
- Translational Medicine
- Medical Science Liaisons
- Asset Management
- Preclinical Staging Development
- Source Management
- Research and Development
- Regulatory Affairs
- Patient Advocacy and Networks
- Legislative Health Aids
- Strategic Partnerships
- Cannabis Clinical Trial Management/ Operations
- Clinical Research
- Medical/Clinical Affairs
- Personalized Medicine
- Patient Advocacy/Access
- Commercial Operations
- Lab Management
- Toxicology

This conference is also of interest to:

- Clinical Labs
- Data Analysis Information Technology
- Clinical Research Organizations
- Regulatory Consultants
- Marketing Firms
- Contract Manufacturing

8:00 Registration and Continental Breakfast

8:45 Conference Co-Chairpersons' Opening Remarks

Dean Petkanas, *Chief Medical Officer,* **KANNALIFE SCIENCES**

Bruce Bloom, *CEO,* **CURES WITHIN REACH**

9:00 **Gain Insight into a Growing Market Within Existing Regulatory Frameworks**

- Understand the current state of regulation
- Recognize the limitations of clinical development
- The future of cannabinoid therapeutics
- Gain a profound understanding of the cannabis market growth

Dean Petkanas, *Chief Medical Officer,* **KANNALIFE SCIENCES**

9:45 **Monitor Governmental Awareness and Legislative Research Options**

- Updates in current legislative standards
- Proposed legislation, legislative branch overview
- Attorney General position and standards enforcement stance

Brian Fisher, *VP of Operations and Corporate Partnerships,* **THE STURGE-WEBER FOUNDATION**

10:30 Networking Break

11:00 **Understand Cannabis Chemical Composition in Order to Develop Industrial Standards**

- Lab information management for cannabis quality control
- Understand chemical components and develop standards
- Critical tools for lab management with cannabis
- Quality control from growth to oil and review synthetic options

Kimberly Lincoln, *Manufacturing Scientist,* **ROCHE**

11:45 **Review the Barriers and Routes to Success for Efficacy Research**

- PTSD interim research results
- Neuro protection and the military
- Geriatric population quality of life improvement research
- Barrier Busters
- FDA, NIH and patentable compounds

Thoma Kikis, *Chief Marketing Officer,* **KANNALIFE**

12:30 Luncheon

1:30 **Breakout Groups**

- Group 1: Roundtable option on how to attain rapid legalization
- Group 2: What activities legislatively support research and increased research locations
- Group 3: Consortium topics and successful partnerships to obtain NIH and/or DoD funding

Veronica Arroyave, *Sr. Director, Global Health Programs,* **PARTNERSHIP FOR QUALITY MEDICAL DONATIONS**

2:30 **Ensure Compliance in Cannabis Marketing**

- Cannabis producers and retailers have incorrectly understood the limits of FDA's authority as it applies to the promotion of cannabis products
- Ensure that no direct disease claims are made
- Overview of FDA cracking down on these claims and issuing warning letters
- FDA oversight as it relates to promotional marijuana claims
- Impact of FDA regulation and the types of discussions that can be appropriately conducted

Darshan Kulkarni, Pharm.D., M.S., Esq., *Advisor,* **AMERICAN SOCIETY OF CANNABIS PHARMACISTS**

3:15 Networking Break

4:00 **Accelerate Cannabis Compound Approval for Rare Diseases**

- Steps toward licensing
- Partnering with FDA, patient groups and institutions Increasing compliance, faster trial enrollment, minimize patient fallout
- Rare Disease Indication which can lead to shorter timeline
- Legislative support through multiple patient advocacy groups

4:45 **Interactive Partnerships Discussion: Maximize Strategic Partnerships in Order to Ensure Patient Safety and Launch a Successful Product**

- Ensure high-priority patient safety
- Review of regulatory landscape
- Setting the stage for technology advancements
- Impact of all stakeholders to continue cannibas support

Dr. Bruno Battistini, *President, CEO and Scientific Director,* **NEW BRUNSWICK HEALTH RESEARCH FOUNDATION**

5:30 Day One Concludes

8:00 Registration and Continental Breakfast

8:45 Conference Co-Chairpersons' Recap of Day One

Dean Petkanas, *Chief Medical Officer,* **KANNALIFE SCIENCES**

Bruce Bloom, *CEO,* **CURES WITHIN REACH**

9:00 **Understand Why State and Federal Governments Must Work Together to Align Regulations**

- Cost implications and effects on Healthcare
- Overview of safety and quality controls in medicinal cannabanoids
- Understand current legislations

Elias Jackson, Ph.D., *CEO,* **VYRIPHARM BIOPHARMACEUTICAL**

9:45 **Forecast the Future of Lab Research in Cannabidiol and Improvements in Analytics and Quality**

- Lab information management for cannabis quality control
- Critical tools for lab management with cannabis
- Public vs. private cannabis testing
- Quality control from growth to oil and review of the synthetic options

10:30 Networking Break

11:00 **Update QC and Patient Experience Communications for Medical Cannabis**

- Enhance cannabidiol patient case study in seizures
- CBD vs. alcohol case study reviewed
- Medicinal cannabidiol communications and branding

Mark Reichman, *EVP, Client Services Director,* **GUIDEMARK HEALTH,** *Cannabis Patient Advocate*

11:45 **Innovative Treatments for Patients Through Drug Repurposing**

- Opportunities for partnerships in advancing science
- Alzheimer's, Anxiety and Answers
- Partnering results: Israel, Canada and the U.S.

Bruce Bloom, *CEO,* **CURES WITHIN REACH**

12:30 Luncheon

1:30 **Panel Discussion: Regulatory Review: Current Legal Questions and Likely Future Developments**

PANEL

- Observe the current state of cannabis within the federal government
- Identify current and future regulations
- Provide an in-depth look at future cannabis practices

Lezli Engelking, *President and Founder,* **FOCUS**

Douglas Brenneman, *Scientific Advisory Board,* **KANNALIFE SCIENCES**

Jeremy Unruh, *General Counsel and Chief Compliance Officer,* **PHARMACANN**

2:30 **Integrate Medical Cannabis With Traditional Medicine**

- Understand the cannabis components that can impact a treatment
- Explore how doses can be impacted
- Minimize side effects

Jerry Bryant, *Managing Member,* **VYRIPHARM BIOPHARMACEUTICAL**

3:15 Networking Break

4:00 **Utilize Crowdsourcing in Response to Federal Research Restrictions**

- Accelerate our understanding of the health impacts of cannabis
- Utilize mobile health, electronic medical records, and artificial intelligence for crowdsourcing
- International cannabis research landscape and how to leverage strategic strengths amongst nations
- Formulations (whole plant vs. pure compounds)
- IP/commercialization of cannabis-based therapeutics
- Preferred delivery routes

Jeffrey Chen, *Director,* **UCLA CANNABIS RESEARCH INITIATIVE**

4:45 Congress Concludes

Media Partners

Cannabis and Cannabinoid Research — Mary Ann Liebert, Inc. publishers

NEW CANNABIS VENTURES

MEDtube — sharing medical knowledge™

420 MAGAZINE® — CREATING CANNABIS AWARENESS SINCE 1993

pharmaLEADERS — News. Resources. Community.

pharmaphorum — bringing healthcare together

PharmaVOICE

www.PharmCast.com — Pharmaceutical Internet

PM360 — THE ESSENTIAL RESOURCE FOR PHARMA MARKETERS

TECHNOLOGY NETWORKS

VENUE INFORMATION

Hilton San Francisco Airport Bayfront
600 Airport Boulevard | Burlingame, CA 94010

To make reservations, please call 1-800-HILTONS and request the negotiated rate for **ExL's March Meetings**. You may also make reservations online using the following weblink: http://bit.ly/2ysQD5h. The group rate is available until **February 20, 2018**. Please book your room early, as rooms available at this rate are limited.

**ExL Events is not affiliated with Exhibition Housing Management (EHM)/Exhibitors Housing Services (EHS) or any third-party booking agencies, housing bureaus or travel companies. ExL Events is affiliated with event company Questex, LLC. In the event that an outside party contacts you for any type of hotel or travel arrangements, please disregard these solicitations and kindly email us at info@exlevents.com. ExL has not authorized these companies to contact you and we do not verify the legitimacy of the services or rates offered. Please book your guest rooms through ExL's reserved guest room block using the details provided.*

Registration Fees for Attending ExL's Cannabis Partnerships Congress

EARLY BIRD PRICING—*Register by January 26, 2018*	
Life Science	**$1,595**
Service Providers	**$1,895**
Academic / Non-Profit	**$1,195**
STANDARD PRICING	
Life Science	**$1,795**
Service Providers	**$2,095**
Academic / Non-Profit	**$1,395**
ONSITE PRICING	
Life Science	**$1,995**
Service Providers	**$2,295**
Academic / Non-Profit	**$1,595**

Group Discount Program

Save 25% per person when registering four

For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register four at one time). This is a savings of 25% per person.

Save 15% per person when registering three

Can only send three? You can still save 15% off every registration.

Offers may not be combined.
Early Bird rates do not apply.
To find out more about how you can take advantage of these group discounts, contact our offices at (201) 871-0474.

March 12-13, 2018

Hilton San Francisco Airport Bayfront | San Francisco, CA

Cannabis Congress

REGISTRATION
to register CLICK HERE or

Call: 201 871 0474
fax: 253 663 7224
email: register@pmaconference.com/
web: http://pmaconference.com/
Mail: POB 2303 Falls Church Va 22042

❑ YES! Register me for this conference!

Name: _____ Title: _____

Company: _____ Dept.: _____

Address: _____

City: _____ State: ____ Zip: _____

Email: _____

Phone: _____ Fax: _____

Method of Payment: ❑ Check ❑ Credit Card

Card Type:

❑ MasterCard ❑ Visa ❑ Discover ❑ AMEX

Card Number: _____

Exp. Date: _____ CVV: _____

Name on Card: _____

Signature: _____

CONFERENCE CODE: C1033

TERMS AND CONDITIONS: By registering for an ExL Events ("ExL") event, you agree to the following set of terms and conditions listed below:

REGISTRATION FEE: The fee includes the conference, all program materials, and designated continental breakfasts, lunches and refreshments.

PAYMENT: Please make checks payable to: "PMA" You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options.

Please Note: There will be an administrative charge of $300 to substitute, exchange and/or replace attendance badges with a colleague within five business days of any ExL conference.

CANCELLATION AND REFUND POLICY: If you cancel your registration for an upcoming ExL event, the following policies apply, derived from the Start Date of the event:

- Four weeks or more: A full refund (minus a $295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date.
- Less than four weeks: A voucher to another ExL event valid for 12 months from the voucher issue date.
- Five days or less: A voucher (minus a $395 processing and documentation fee) to another ExL event valid for 12 months from the voucher issue date.

To receive a refund or voucher, please contact our offices at (201) 871-0474.

CREDIT VOUCHERS: Credit vouchers are valid for 12 months from date of issue. Credit vouchers are valid toward one (1) ExL event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is not applicable now or in the future. Once a credit voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees' behalf, the credit voucher will no longer be valid.

ExL Events does not and is not obligated to provide a credit voucher to registered attendee(s) who do not attend the event they registered for unless written notice of intent to cancel is received and confirmed prior to the commencement of the event.

SUBSTITUTION CHARGES: There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare, hotel or any other expenses incurred by registrants.

ExL Events' liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date, content, speakers and/or venue.

*The opinions of ExL's conference speakers do not necessarily reflect those of the companies they represent, nor ExL Events.

Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL's designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redistribution to other outlets without the express written permission of ExL's designated speaking parties. Neither ExL nor its content providers and/or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. EXL EVENTS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of, or endorse the views or opinions given by any third-party content provider. ExL presentations may point to other websites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites.